CNX Therapeutics’ €56.5m Acquisition of Eisai’s Rights in Loxapac and Parkinane

Georgio Naffaa
Tagged:

Simmons & Simmons advised Eisai on the divestment.Eisai S.A.S, the French subsidiary of Eisai Co., Ltd., has transferred its rights to Loxapac (loxapine) and Parkinane LP…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Georgio Naffaa

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here